Skip to main content
OpenTrials
Completed

NCT Number: NCT07398755

Prospective, Non-interventional Study Assessing Periorbital Rejuvenation Procedure

The goal of this observation is to assess the time course of holistic extended periorbital rejuvenation using botulinum toxin A, cross-linked hyaluronic acid and polynucleotides corresponding to the application in routine practice in adults. It will also document the safety of treatment procedure and patient satisfaction.

The main questions it aims to answer are:

* How does a holistic extended periorbital rejuvenation procedure using botulinum toxin A, cross-linked hyaluronic acid filler, and polynucleotides change skin wrinkling around the eye area over time (particularly after 8 and 22 weeks)? * How does the treatment affect the severity of dynamic glabellar lines at 8 and 22 weeks? * Does the procedure improve midface volume deficiency after 8 and 22 weeks? * How satisfied are participants with the overall rejuvenation treatment?

The investigator will observe the combination treatment of a drug Letybo® and medical devices PhilArt® Eye and Saypha® Volume Plus Lidocaine within their approved indications (non-interventional study, on-label use). The combination treatment aims to rejuvenate and improve the eye area holistically in patients coming routinely to the clinic.

Participants will:

* take PhilArt® Eye on Week 0 (Baseline), 3 and 6; Saypha® Volume Plus Lidocaine on Week 0 (Baseline); Letybo® on Week 6. * visit the clinic on Week 0 (Baseline), 3, 6, 8 and 22 as per clinical practice for checkups and satisfaction assessment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Glabellar Lines Midface Volume Deficiency Periorbital Wrinkling

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

YUVELL

Vienna, State of Vienna, 1010, Austria

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years or older at time of treatment.
  • At least mild periorbital skin wrinkling, mild frown lines at maximum frown and mild.

midface volume deficiency as assessed by the investigator

  • Subject has a stable medical condition with no uncontrolled systemic disease.
  • Willingness to participate in the routine follow-up after 8 weeks and 22 weeks and a signed informed consent form.
  • Subject already visiting the clinic for the specific treatment.

Exclusion criteria

  • Pregnancy and breast feeding.
  • Neuromuscular disease (e.g. myasthenia gravis, Eaton - Lambert syndrome).
  • Known impairment of blood coagulation.
  • Drooping eyelid.
  • Known allergy to botulinum toxin or human albumin (blood protein).
  • Presence of acute infection or inflammation at the proposed injection sites.
  • Botulinum toxin treatment in the glabella within the last 16 weeks.
  • HA- Filler treatment in the midface or periorbital area within the last 6 months.
  • Patients with a history of autoimmune disease or who are receiving immune therapy.
  • History of hypersensitivity to hyaluronic acid, lidocaine hydrochloride or other amidetype local anaesthetics.
  • History of fish product allergy.

Treatment and study plan

Letybo®

Drug

Drug is used as part of routine clinical care. This observational study does not assign or modify treatment; it observes outcomes associated with drug use.

Other names: BoNT/A, botulinum toxin A, Letibotulinumtoxin A

Philart® Eye

Device

Device is used as part of routine clinical care. This observational study does not assign or modify treatment; it observes outcomes associated with device use.

Other names: polynucleotide

Saypha® Volume Plus Lidocaine

Device

Device is used as part of routine clinical care. This observational study does not assign or modify treatment; it observes outcomes associated with device use.

Other names: hyaluronic acid with lidocaine

Primary outcomes

  1. Change in skin wrinkling in periorbital area at Week 8

    Time frame: Week 8

    Change in the percentage of skin wrinkling in the periorbital area from baseline to Week 8, as assessed using VISIA® skin analysis. Skin wrinkling is quantified as a percentage-based measurement derived from standardized VISIA imaging of the area around the eye. The outcome is expressed as the percent change relative to baseline, with higher percentages indicating an improvement, which equals a reduction in skin wrinkling.

Secondary outcomes

  1. Change in skin wrinkling in the periorbital area at Week 22

    Time frame: Week 22

    Change in the percentage of skin wrinkling in the periorbital area from baseline to Week 22, as assessed using VISIA® skin analysis. Skin wrinkling is quantified as a percentage-based measurement derived from standardized VISIA imaging of the area around the eye. The outcome is expressed as the percent change relative to baseline, with higher percentages indicating an improvement, which equals a reduction in skin wrinkling.

  2. Change in severity of dynamic glabellar lines at Week 8 and Week 22

    Time frame: Week 8, Week 22

    Change from baseline in everuty of glabellar lines at maximum frowning, measured at Week 8 and Week 22 using using the Facial Wrinkle Score (FWS).

    Severity of glabellar lines is quantified by comparing FWS scores at baseline and follow-up visits to assess severity grade during maximum frowning.

    The Facial Wrinkle Scale (FWS) is a validated photo-numeric scale ranging from 0 to 3, where higher scores indicate greater wrinkle severity.

  3. Change from baseline in midface volume deficit severity, assessed at Week 8 and Week 22 by the investigator using the Midface Volume Deficit Severity Score (MVDSS)

    Time frame: Week 8, Week 22

    Change in investigator-assessed Midface Volume Deficit Severity Score (MVDSS) from baseline to Week 8.

    The MVDSS is used to evaluate the degree of midface volume deficiency based on clinical assessment. The outcome is expressed as the change in MVDSS score relative to baseline at each follow-up time point, with lower scores indicating a reduction in midface volume deficit severity.

    The Midface Volume Deficit Scale is a validated 5-point rating photo-numeric scale ranging from grade 0 to grade 4, where higher scores indicate greater very severe volume deficit.

  4. Patient satisfaction with treatment assessed using a clinic-internal patient satisfaction questionnaire

    Time frame: Week 22

    Patient satisfaction with the treatment as assessed by participants using the clinic-internal questionnaire titled "Patient Satisfaction Questionnaire". The questionnaire consists of 5 questions evaluating the participant's overall satisfaction with the treatment outcome. Each item is rated on a numeric ordinal scale from 1 to 5, where lower scores indicate higher patient satisfaction.

Sponsors and collaborators

Lead sponsor

Yuvell

Other

Collaborators

  • Croma-Pharma GmbH

Registry information

Official study title

A Prospective, Non-interventional, Single-Centre Study Assessing the Time Course of a Holistic Extended Periorbital Rejuvenation Procedure

Important dates

Study start
2025
Primary completion
2025
Study completion
2026
First posted
Feb 10, 2026
Registry last updated
Mar 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.